When was Lexent Bio founded?

Lexent Bio was founded in 2017.

Where is Lexent Bio located?

Lexent Bio is headquartered in San Diego, United States.

How many employees does Lexent Bio have?

As of Aug 31, 2026, the latest employee count at Lexent Bio is 1.

Where does Lexent Bio rank among its competitors?

Lexent Bio ranks 237th amongst 274 active competitors, of which 88 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Lexent Bio?

Lexent Bio's top competitors include Guardant Health, Exact Sciences and GRAIL. Among them, GRAIL secured the most recent funding round in June, 2026.

Lexent Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of bioinformatics and genomic science to diagnose cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, and immunotherapies.

Website: lexentbio.com
Social
Email ID: *****@lexentbio.com

Key Metrics

Founded Year

2017

Location

San Diego, United States

Stage

Acqui-Hired

Investors

Threshold & 14 more

Ranked

237^th among 274 active competitors

Employee Count

1 as on Aug 31, 2026

Similar Companies

Exact Sciences & 249 more

View Lexent Bio's full profile

Lexent Bio is a funded company. Lexent Bio has 15 institutional investors.

View details of Lexent Bio's funding rounds and investors

The founders of Lexent Bio is Samuel Levy.

Here are the details of Lexent Bio's key team members:

Samuel Levy: Founder of Lexent Bio.
Ken Nesmith: CEO of Lexent Bio.

View details of Lexent Bio's Founder profiles and Board Members

Lexent Bio's employee count trend

Lexent Bio has 1 employees as of Aug 26. Here is Lexent Bio's employee count trend over the years:

Uncover Lexent Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lexent Bio include Guardant Health, Exact Sciences and GRAIL. Here is the list of Top 10 competitors of Lexent Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	79/100
2nd	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
3rd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	69/100
4th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
5th	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, Olympus & 6 others	67/100
6th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
7th	OncoCyte 2009, Irvine (United States), Public	Developer of non-invasive diagnostic tests solutions for the treatment of cancer	$15.3M	Geode Capital, Connor, Clark & Lunn Financial Group ... & 5 others	66/100
8th	Scipher Medicine 2014, Waltham (United States), Series D	Provider of precision medicine based on liquid biopsy test	$233M	Northpond Ventures, Cowen & 14 others	65/100
9th	Saga Diagnostics 2016, Morrisville (United States), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 11 others	64/100
10th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	DFJ Growth, Orbimed & 19 others	64/100
237th	Lexent Bio 2017, San Diego (United States), Acqui-Hired	Provider of bioinformatics and genomic science to diagnose cancer	-	Threshold, Uber & 13 others	23/100